A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
James Chih‐Hsin Yang, Leah R. Haworth, Richard Mark Sherry et al. · New England Journal of Medicine · 2003
BACKGROUND: Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma. METHODS: A randomized, double-blind, phase 2 trial was conducted comparing placebo with bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two weeks; the time to progression of disease and the response rate were primary end points. Crossover from placebo to antibody treatment was allowed, and survival was a secondary end point. RESULTS: Minimal toxic effects were seen, with hypertension and asymptomatic proteinuria predominating. The trial was stopped after the interim analysis met the criteria for early stopping. With 116 patients randomly assigned to treatment groups (40 to placebo, 37 to low-dose antibody, and 39 to high-dose antibody), there was a significant prolongation of the time to progression of disease in the high-dose--antibody group as compared with the placebo group (hazard ratio, 2.55; P<0.001). There was a small difference, of borderline significance, between the time to progression of disease in the low-dose--antibody group and that in the placebo group (hazard ratio, 1.26; P=0.053). The probability of being progression-free for patients given high-dose antibody, low-dose--antibody, and placebo was 64 percent, 39 percent, and 20 percent, respectively, at four months and 30 percent, 14 percent, and 5 percent at eight months. At the last analysis, there were no significant differences in overall survival between groups (P>0.20 for all comparisons). CONCLUSIONS: Bevacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer.
Cited by 2,697 works. doi:10.1056/nejmoa021491 Open-access PDF
Authors
- James Chih‐Hsin Yang
- Leah R. Haworth
- Richard Mark Sherry
- Patrick Hwu
- Douglas J. Schwartzentruber
- Suzanne Louise Topalian
- Seth M. Steinberg
- Helen X. Chen
- Steven A. Rosenberg
References
- A Multiple Testing Procedure for Clinical Trials
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
- The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
- Mutations of the VHL tumour suppressor gene in renal carcinoma
- Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
- Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
- Molecular and biological properties of vascular endothelial growth factor
- Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.
- Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer
- Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor